One of the people who fought for Kalydeco to be funded is Eddie Porter whose two and half-year-old son Otis has cystic fibrosis.
Porter told RNZ's Checkpoint the news was exciting for his son, who might just get a new chance at life.
"There's also just such excitement for all the other families in New Zealand that have the same condition.
"Kalydeco being funded is a great source of hope that other medicines for rare disorders might be funded too, that other families can share in the excitement that we're feeling right now."
The drug means Otis is much less likely to get sick and a lot more resilient for illnesses that he does get.
"A lot less pain, a lot less suffering, a lot less time away from school and friends," Porter said.
"The life expectancy as it stands in New Zealand for someone [with cystic fibrosis] is 37 years, and the sky's the limit for people on Kalydeco.
"Probably decades added to that if people have access to Kalydeco early enough."
The family had been campaigning for about two years for Pharmac to fund the drug.
Without funding help, Kalydeco would cost the family $360,000 a year.
"That's just so far beyond the bounds of anything we could reasonably think to afford," Porter told Checkpoint.
He said they were looking forward to Otis getting the drug in March.